Home > Result Summaries: Compounds > GSK961081 Result Summaries: GSK961081 GSKStudy ID Phase Title Summary (Download) 104865 phase 1 A study to evaluate the safety, tolerability, systemic pharmacokinetic profile and pharmacodynamics of single and repeat inhaled doses of GSK961081 in healthy subjects (0 citation(s)) 113423 phase 1 A randomised, double-blind, double-dummy, single dose, four way cross-over study to compare the pharmacokinetics and pharmacodynamics of GSK961081 and fluticasone propionate when administered alone, concurrently and as a combination blend in healthy subjects (0 citation(s)) 115032 phase 2 A 4-week Dose-Ranging, Dose-Interval, Efficacy, Safety and Tolerability Study of GSK961081 in Subjects with Chronic Obstructive Pulmonary Disease (COPD) (1 citation(s)) MAB104958 phase 2 See Detailed Description (0 citation(s)) MAB108115 phase 1 A randomised, double-blind, dose escalating study in healthy volunteers to assess the safety, tolerability, extra pulmonary pharmacodynamics and pharmacokinetics of single doses of GSK961081 (succinate salt) (0 citation(s)) MAB110123 phase 2 A randomized, double-blind, crossover study to investigate the bronchodilatation post-inhalation of GSK961081 alone and with the addition of cumulative doses of short acting bronchodilators (salbutamol and ipratropium bromide) in patients with COPD (0 citation(s)) MAB110553 phase 1 A study to investigate the relative pharmacological activity of aninhaled B2-agonist/anticholinergic dual pharmacophore inhealthy volunteers (0 citation(s))
